TY - JOUR
T1 - Safety of magnetic resonance imaging one to three days after bare metal and drug-eluting stent implantation
AU - Porto, Italo
AU - Selvanayagam, Joseph
AU - Ashar, Vaishali
AU - Neubauer, Stefan
AU - Banning, Adrian P.
PY - 2005/8/1
Y1 - 2005/8/1
N2 - Despite emerging evidence that magnetic resonance imaging (MRI) is safe within 8 weeks after bare metal coronary stenting, there are limited data on the safety of MRI imaging very early (1 to 3 days) after stent implantation and no published studies to date on the safety of MRI after insertion of drug-eluting stents (DESs). Forty-nine patients underwent cardiovascular MRI (1.5 T) at a median of 1 day after complex percutaneous coronary intervention. The average number of stents per patient was 2.2 ± 1.1, and the average stent length per patient was 37.8 ± 19.7 mm. In 15 of these patients <1 DES was used: paclitaxel DESs in 14 and sirolimus DESs in 1. In the DES group, the average number of stents was 1.75 ± 1.0 per patient (3 patients received 3 DESs), and average DES length was 36.5 ± 14.8 mm per patient. No acute thrombosis was recorded, and at 9-month clinical follow-up only 2 patients (4%) developed adverse events (1 target vessel restenosis and 1 nontarget vessel revascularization); these patients were in the non-DES group.
AB - Despite emerging evidence that magnetic resonance imaging (MRI) is safe within 8 weeks after bare metal coronary stenting, there are limited data on the safety of MRI imaging very early (1 to 3 days) after stent implantation and no published studies to date on the safety of MRI after insertion of drug-eluting stents (DESs). Forty-nine patients underwent cardiovascular MRI (1.5 T) at a median of 1 day after complex percutaneous coronary intervention. The average number of stents per patient was 2.2 ± 1.1, and the average stent length per patient was 37.8 ± 19.7 mm. In 15 of these patients <1 DES was used: paclitaxel DESs in 14 and sirolimus DESs in 1. In the DES group, the average number of stents was 1.75 ± 1.0 per patient (3 patients received 3 DESs), and average DES length was 36.5 ± 14.8 mm per patient. No acute thrombosis was recorded, and at 9-month clinical follow-up only 2 patients (4%) developed adverse events (1 target vessel restenosis and 1 nontarget vessel revascularization); these patients were in the non-DES group.
UR - http://www.scopus.com/inward/record.url?scp=23044500421&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.03.077
DO - 10.1016/j.amjcard.2005.03.077
M3 - Article
C2 - 16054459
AN - SCOPUS:23044500421
SN - 0002-9149
VL - 96
SP - 366
EP - 368
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -